Ballwin, MO, United States of America

Renhe Qiu

This inventor holds 1 USPTO granted patent. Top assignees: Humanwell Pharmaceutical US, Yichang Humanwell Pharmaceutical Co., Ltd.. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Renhe Qiu: Innovator in Pharmaceutical Formulations

Introduction

Renhe Qiu is a notable inventor based in Ballwin, MO (US). He has made significant contributions to the field of pharmaceuticals, particularly in pain management. His work focuses on innovative formulations that enhance the delivery and effectiveness of analgesic medications.

Latest Patents

Renhe Qiu holds a patent for "Pharmaceutical formulations containing Nalbuphine." This patent describes new pharmaceutical formulations, their preparation, and their use for pain treatment. Specifically, it details formulations of the analgesic drug Nalbuphine designed for intranasal administration. This innovative approach aims to improve patient outcomes in pain management.

Career Highlights

Throughout his career, Renhe Qiu has worked with prominent companies in the pharmaceutical industry. He has been associated with Yichang Humanwell Pharmaceutical Co., Ltd. and Humanwell Pharmaceutical US. His experience in these organizations has contributed to his expertise in developing effective pharmaceutical solutions.

Collaborations

Renhe Qiu has collaborated with several professionals in his field, including Xueming Wu and Hong Du. These partnerships have facilitated the exchange of ideas and advancements in pharmaceutical research.

Conclusion

Renhe Qiu's contributions to pharmaceutical formulations, particularly with Nalbuphine, highlight his innovative spirit and dedication to improving pain management. His work continues to influence the pharmaceutical industry and enhance patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…